Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699461 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
A Phase 2 study, sponsored by ADC Therapeutics S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04699461 is a Phase 2 study that was terminated before completion, run by ADC Therapeutics S.A.. The registered enrollment target is 6 participants.
The verdict
NCT04699461, a Phase 2 study, was terminated before completion, sponsored by ADC Therapeutics S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
Interventions
- DRUG Loncastuximab Tesirine
- DRUG Idelalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2022-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699461
The ClinicalTrials.gov registry entry for NCT04699461 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loncastuximab Tesirine is the first listed.
NCT04699461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04699461 about?
NCT04699461 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma". This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
What is the current status of trial NCT04699461?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-11-04. Estimated completion is 2022-11-25.
What interventions are being tested in trial NCT04699461?
The interventions under investigation include: Loncastuximab Tesirine (DRUG), Idelalisib (DRUG).
Who is sponsoring clinical trial NCT04699461?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.